SCHEMBL8656137

SCHEMBL8656137

Cc1cn(C(C)C)c(=S)[nH]c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 7/20 0.35
MAPT P10636 3/20 0.35
HPGD P15428 3/20 0.35
KDM4E B2RXH2 3/20 0.34
HCRTR1 O43613 1/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TYMP P19971 2/20 0.34
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33
ALB P02768 1/20 0.33
POLB P06746 1/20 0.33
ADRA1A P35348 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784395 0.80 MAPK1 (0.43) SMN1; SMN2ALDH1A1HPGDMAPK1TYMP
SCHEMBL21418605 0.79 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL10105028 0.74 KMT2A (0.40) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL22571159 0.73 ALDH1A1 (0.34) ALDH1A1MAPTHPGDKDM4EHCRTR1
SCHEMBL23482940 0.72 MAPK1 (0.36) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL28216800 0.72 MAPK1 (0.40) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL28021080 0.72 TK1 (0.36) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL22460363 0.70 TYMP (0.34) ALDH1A1TYMPLMNAALBPOLB
SCHEMBL22759941 0.69 MAPK1 (0.41) SMN1; SMN2ALDH1A1HPGDMAPK1TYMP
SCHEMBL4194708 0.69 MAPK1 (0.41) ALDH1A1HPGDGAAMAPK1TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773132-B2 Cyclic di-nucleotides as stimulator of interferon genes modulators BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2023-10-03 US disclosed
US-20220073931-A1 ANTISENSE OLIGONUCLEOIDES OF GLUTATHIONE S-TRANSFERASES FOR CANCER TREATMENT ATSO CORP AFFAIRS S A DE C V (MX) 2022-03-10 US disclosed
US-20200331957-A1 CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS AJ SCIENCES (YIXING) CO., LTD (CN) 2020-10-22 US disclosed
EP-2643317-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-10-02 EP disclosed
WO-2012071519-A1 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-31 WO disclosed
US-20110250138-A1 SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND ALNYLAM PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110250138-A1 SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND SLC40A1, SLCO1B1, SLCO2A1 SMN1; SMN2 737/4885MEN1 786/4885KMT2A 2705/4885
US-20200331957-A1 CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS STING1, IRF3, CGAS SMN1; SMN2 4870/4885MEN1 4490/4885KMT2A 1936/4885
US-11773132-B2 Cyclic di-nucleotides as stimulator of interferon genes modulators STING1, IRF3, CGAS SMN1; SMN2 4870/4885MEN1 4490/4885KMT2A 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.